AAPL

TSLA

AMZN

META

AMD

NVDA

PEP

COST

ADBE

GOOG

AMGN

HON

INTC

INTU

NFLX

ADP

SBUX

MRNA

Markets

TGTX

This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop

March 16, 2026 — 04:14 pm EDT

Written by

Jonathan Ponciano for

The Motley Fool->

Key Points

- ACT Capital Management added 268,875 shares of TG Therapeutics in the fourth quarter.

- The quarter-end value of the position rose by $8,015,164, reflecting the new stake in TG Therapeutics.

- The new position ranks as the fund’s fifth-largest holding as of the latest filing.

- 10 stocks we like better than TG Therapeutics ›

On February 17, 2026, ACT Capital Management disclosed a new position in TG Therapeutics (NASDAQ:TGTX), acquiring 268,875 shares worth $8,015,164.

What happened

According to a filing with the Securities and Exchange Commission dated February 17, 2026, ACT Capital Management established a new position in TG Therapeutics during the prior quarter, acquiring 268,875 shares. The quarter-end value of the stake stood at $8,015,164, reflecting the full impact of the new holding’s valuation.

What else to know

- This was a new position for the fund, representing 6.5% of its $123.67 million in reportable U.S. equity assets as of December 31, 2025.

- Top holdings after the filing:- NASDAQ: KRYS: $14.92 million (12.5% of AUM)

- NYSE: CVX: $11.96 million (10.1% of AUM)

- NYSE: XOM: $9.93 million (8.4% of AUM)

- NASDAQ: ABVX: $8.62 million (7.3% of AUM)

- NASDAQ: TGTX: $8.02 million (6.5% of AUM)

- As of Monday, shares of TG Therapeutics were priced at $28.58, down 30% over the past year and well underperforming the S&P 500’s roughly 18% gain in the same period.

Company overview

MetricValuePrice (as of Monday)$28.58Market capitalization$4.6 billionRevenue (TTM)$616.3 millionNet income (TTM)$447.2 millionCompany snapshot

- TG Therapeutics develops and commercializes therapies for B-cell malignancies and autoimmune diseases, including monoclonal antibodies and targeted small molecules.

- The firm’s revenue is primarily generated through the sale of proprietary pharmaceutical products and licensing agreements within the biotechnology sector.

- It serves healthcare providers and patients with a focus on oncology and immunology markets.

TG Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of innovative therapies for hematologic cancers and autoimmune disorders. The company leverages a pipeline of monoclonal antibodies and targeted therapies to address unmet medical needs in oncology and immunology. With a growing commercial footprint and strategic partnerships, TG Therapeutics aims to expand its market presence through both proprietary product launches and collaborative agreements. Its focus on novel mechanisms of action and differentiated clinical profiles underpins its competitive positioning in the biotechnology industry.

What this transaction means for investors

TG Therapeutics appears to be moving through a transition that could help turn its promising therapy into a strong commercial engine. The company’s multiple sclerosis treatment BRIUMVI has rapidly become the core of its business. Product sales reached roughly $606.9 million in 2025, nearly doubling in a year and helping push total annual revenue to about $616.3 million as adoption accelerated among neurologists treating relapsing forms of multiple sclerosis. The drug also delivered strong momentum late in the year, generating $182.7 million in U.S. revenue in the fourth quarter alone.

Still, shares have struggled over the past year, as guidance disappointed investors. The company is targeting approximately $875 million to $900 million in total global revenue for 2026, driven largely by continued BRIUMVI adoption and expanding international commercialization. But with the disappointment priced in, if TG surpasses the latest projections, it could be due for a turnaround, and that might be what ACT is betting on.

Within the broader portfolio, the position fits alongside several healthcare and biotech names, including Krystal Biotech and Abivax, which together form a meaningful allocation to innovative drug developers and suggest a willingness to embrace clinical and regulatory risk in pursuit of outsized returns.

Should you buy stock in TG Therapeutics right now?

Before you buy stock in TG Therapeutics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and TG Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $514,000!* Or when Nvidia made this list on April 15, 2005... if